Cognitive Dysfunction in Parkinson’s Disease

doi:10.1017/9781009039291.008

Chapter 7 - Cognitive Dysfunction in Parkinson’s Disease

Published online by Cambridge University Press: 05 March 2022

Damon Salzman and

Shakeel Tabish

Edited by

Néstor Gálvez-Jiménez ,

Amos D. Korczyn and

Ramón Lugo-Sanchez

Show author details

Néstor Gálvez-Jiménez: Affiliation:
Florida International University
Amos D. Korczyn: Affiliation:
Tel-Aviv University
Ramón Lugo-Sanchez: Affiliation:
Cleveland Clinic

Book contents

Get access

Summary

In 1817, the English surgeon Dr James Parkinson penned his now classic work, “An Essay on the Shaking Palsy.” He describes the condition as, “an involuntary tremulous motion, with lessened muscular power, in parts not in action, and even when supported; with a propensity to bend the trunk forwards, and to pass from a walking to a running pace; the senses and intellects being uninjured” [1].

The description of this paralysis agitans (later renamed as Parkinson’s disease by Jean Marie Charcot) has largely remained unchanged today over 200 years later. However, we now realize that the latter part, that the senses and intellect being uninjured, is incorrect. This chapter will summarize the prevalence, incidence, pathophysiology, and the scope of the cognitive changes that are seen in this disease.

Type: Chapter
Information: Non-motor Parkinson's Disease , pp. 66 - 77

DOI: https://doi.org/10.1017/9781009039291.008 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Parkinson, J. An Essay on the Shaking Palsy. Sherwood, Neely and Jones; 1817.Google Scholar

World Health Organization. Global Action Plan on the Global Response to Dementia 2017–2025. Geneva; 2017.Google Scholar

Thaler, A, Posen, J, Giladi, N, et al. Appreciation of humor is decreased among patients with Parkinson’s disease. Parkinsonism Relat Disord 2012; 18(2): 144–148.Google Scholar

Aarsland, D, Zaccai, J, Brayne, C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 2005; 20: 1255–1263.Google Scholar

Cummings, JL. Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. Top Geriatr 1988; 1(1): 24–36.Google Scholar

Aarsland D, , Andersen K, , Larsen, JP, et al. Risk of dementia in Parkinson’s disease. Neurology Mar 2001; 56(6): 730–736.Google Scholar

Hobson, P, Meara, J. Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 2004; 19: 1043–1049.Google Scholar

Aarsland, D, Andersen, K, Larsen, JP, Lolk, A. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3): 387–392.Google Scholar

Butler, TC, van den Hout A, , Matthews, FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology Mar 2008; 70(13): 1017–1022.Google Scholar

Poletti, M, Frosini, D, Pagni, C, et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2012; 83: 601–606.Google Scholar

Muslimović D, , Post B, , Speelman JD, , Schmand B, . Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65(8): 1239–1245.Google Scholar

Foltynie T, , Brayne CEG, , Robbins TW, , Barker RA, . The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN Study. Brain 2004; 127(3): 550–560.Google Scholar

Mayeux, R, Denaro, J, Hemenegildo, N, et al. A population-based investigation of Parkinson’s disease with and without dementia: relationship to age and gender. Arch Neurol 1992; 49(5): 492–497.Google Scholar

Levy, G, Schupf, N, Tang, MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 2002; 51: 722–729.Google Scholar

Anang JBM, , Gagnon JF, , Bertrand, JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 2014; 83(14): 1253–1260.Google Scholar

Jozwiak N, , Postuma RB, , Montplaisir, J, et al. REM sleep behavior disorder and cognitive impairment in Parkinson’s disease. Sleep 2017; 40(8): zsx101.Google Scholar

Anang JBM, , Gagnon JF, , Bertrand, JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 2014; 83(14): 1253–1260.Google Scholar

Alcalay RN, , Caccappolo E, , Mejia-Santana, H, et al. Cognitive performance of GBA mutation carriers with early-onset PD. Neurology 2012; 78(18): 1434–1440.Google Scholar

Chahine, LM, Qiang, J, Ashbridge, E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol 2013; 70(7): 852–858.Google Scholar

Liu, G, Boot, B, Locascio, JJ, et al. Specifically neuropathic Gaucher’s mutations accelerate cognitive decline in Parkinson’s. Ann Neurol 2016; 80: 674–685.Google Scholar

Obi T, , Nishioka K, , Ross, OA, et al. Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 2008; 70(3): 238–241.Google Scholar

Goris, A, Williams‐Gray, CH, Clark, GR, et al. Tau and α‐synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol 2007; 62: 145–153.Google Scholar

Williams-Gray CH, , Evans JR, , Goris, AN, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132(11): 2958–2969.Google Scholar

Aarsland, D, Perry, R, Brown, A, et al. Neuropathology of dementia in Parkinson’s disease: a prospective, community‐based study. Ann Neurol 2005; 58: 773–776.CrossRef Google Scholar PubMed

Apaydin, H, Ahlskog, JE, Parisi, JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59(1): 102–112.Google Scholar

Kövari, E, Gold, G, Herrmann, FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol 2003; 106: 83–88.Google Scholar

Edison, P, Rowe, CC, Rinne, JO, et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11 C] PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331–1338.Google Scholar

Petrou, M, Bohnen, NI, Müller, MLTM, et al. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012; 79(11): 1161–1167.Google Scholar

Kotzbauer, PT, Cairns, NJ, Campbell, MC, et al. Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol 2012; 69(10): 1326–1331.Google Scholar

Irwin, DJ, White, MT, Toledo, JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72: 587–598.Google Scholar

Hall H, , Reyes S, , Landeck, N, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain 2014; 137(9): 2493–2508.Google Scholar

Siderowf A, , Xie SX, , Hurtig, H, et al. CSF amyloid β 1–42 predicts cognitive decline in Parkinson disease. Neurology 2010; 75(12): 1055–1061.Google Scholar

Alves G, , Lange J, , Blennow, K, et al. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology 2014; 82(20): 1784–1790.Google Scholar

Burton, EJ, McKeith, IG, Burn, DJ, O’Brien, JT. Brain atrophy rates in Parkinson’s disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005; 20: 1571–1576.Google Scholar

Nagano-Saito A, , Washimi Y, , Arahata, Y, et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005; 64(2): 224–229.Google Scholar

Beyer, MK, Janvin, CC, Larsen, JP, et al. A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007; 78: 254–259.Google Scholar

Melzer, TR, Watts, R, MacAskill, MR, et al. Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatry 2012; 83: 188–194.Google Scholar

Mori, H. Pathological substrate of dementia in Parkinson’s disease – its relation to DLB and DLBD. Parkinsonism Relat Disord 2005; 11: S41–S45.Google Scholar

Ballard C, , Ziabreva I, , Perry, R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67(11): 1931–1934.Google Scholar

Shimada H, , Hirano S, , Shinotoh, H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009; 73(4): 273–278.Google Scholar

Bohnen, NI, Kaufer, DI, Hendrickson, R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 2006; 253: 242–247.Google Scholar

Bohnen, NI, Kaufer, DI, Ivanco, LS, et al. Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60(12): 1745–1748.Google Scholar

Mattila, PM, Röyttä, M, Lönnberg, P, et al. Choline acetyltransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol 2001; 102: 160–166.Google Scholar

Perry, EK, Curtis, M, Dick, DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1985; 48: 413–421.Google Scholar

Ehrt, U, Broich, K, Larsen, JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurology Neurosurg Psychiatry 2010; 81: 160–165.Google Scholar

Bohnen, NI, Albin, RL, Müller, MLTM, et al. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. JAMA Neurol 2015; 72(2): 194–200.Google Scholar

Morrison, C, Borod, J, Brin, M, et al. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson’s disease (MSPD). J Neural Transm 2004; 111: 1333–1341.Google Scholar

Stern, Y, Richards, M, Sano, M, Mayeux, R. Comparison of cognitive changes in patients with Alzheimer’s and Parkinson’s disease. Arch Neurol 1993; 50(10): 1040–1045.CrossRef Google Scholar PubMed

Levin BE, , Llabre MM, , Reisman, S, et al. Visuospatial impairment in Parkinson’s disease. Neurology 1991; 41(3): 365.Google Scholar

Muslimović D, , Post B, , Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65(8): 1239–1245.Google Scholar

Aarsland D, , Brønnick K, , Larsen, JP, et al. Cognitive impairment in incident, untreated Parkinson disease. Neurology 2009; 72(13): 1121–1126.Google Scholar

Pillon, B, Deweer, B, Agid, Y, Dubois, B. Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol 1993; 50(4): 374–379.Google Scholar

Emre, M, Aarsland, D, Albanese, A, et al.Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–2518.Google Scholar

Tröster, AI, Browner, N. Movement disorders with dementia in older adults. In Ravdin, LD and Katzen HL, (eds.). Handbook on the Neuropsychology of Aging and Dementia. Springer Science + Business Media; 2013, 333–361.Google Scholar

Janvin, CC, Larsen, JP, Salmon, DP, et al. Cognitive profiles of individual patients with Parkinson’s disease and dementia: comparison with dementia with lewy bodies and Alzheimer’s disease. Mov Disord 2006; 21: 337–342.Google Scholar

Lewis, SJG, Foltynie, T, Blackwell, AD, et al. Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005; 76: 343–348.Google Scholar

Aarsland, D, Andersen, K, Larsen, JP, Prevalence, Lolk A. and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3): 387–392.Google Scholar

Fénelon G, , Mahieux F, , Huon R, , Ziégler M, . Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123(4): 733–745.Google Scholar

Aarsland, D, Andersen, K, Larsen, JP, Lolk, A. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3): 387–392.Google Scholar

Aarsland, D, Larsen, JP, Tandberg, E, Laake, K. Predictors of nursing home placement in Parkinson’s disease: a population‐based, prospective study. J Am Geriatr Soc 2000; 48: 938–942.Google Scholar

Emre, M, Aarsland, D, Brown, R, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689–1707.Google Scholar

McKeith, IG, Burn D. Spectrum of Parkinson’s disease, Parkinson’s dementia, and Lewy body dementia. Neurolog Clin 2000; 18(4): 865–883.Google Scholar

McKeith IG, , Dickson DW, , Lowe, J, et al. Diagnosis and management of dementia with Lewy bodies. Neurology 2005; 65(12): 1863–1872.Google Scholar

Noe, E, Marder, K, Bell, KL, et al. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord 2004; 19: 60–67.Google Scholar

Ballard CG, , Aarsland D, , McKeith, I, et al. Fluctuations in attention. Neurology 2002; 59(11): 1714–1720.CrossRef Google Scholar PubMed

Pillon, B, Deweer, B, Agid, Y, Dubois, B. Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol 1993; 50(4): 374–379.Google Scholar

Starkstein, SE, Sabe, L, Petracca, G, et al. Neuropsychological and psychiatric differences between Alzheimer’s disease and Parkinson’s disease with dementia. J Neurol Neurosurg Psychiatry 1996; 61: 381–387.Google Scholar

Cahn-Weiner, DA, Williams, K, Grace, J, et al. Discrimination of dementia with Lewy bodies from Alzheimer disease and Parkinson disease using the Clock Drawing Test. Cog Behav Neurol 2003; 16(2): 85–92.Google Scholar

Mosimann UP, , Mather G, , Wesnes, KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004; 63(11): 2091–2096.Google Scholar

Fénelon G, , Mahieux F, , Huon R, , Ziégler M, . Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 2000; 123 (4): 733–745.CrossRef Google Scholar PubMed

Aarsland, D, Ballard, C, Larsen, JP, McKeith, I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int J Geriat Psychiatry 2001; 16: 528–536.Google Scholar

Engelborghs, S, Maertens, K, Nagels, G, et al. Neuropsychiatric symptoms of dementia: cross‐sectional analysis from a prospective, longitudinal Belgian study. Int J Geriat Psychiatry 2005; 20: 1028–1037.CrossRef Google Scholar PubMed

Aarsland, D, Brønnick, K, Ehrt, U, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36–42.Google Scholar

Gjerstad MD, , Aarsland D, , Larsen, JP. Development of daytime somnolence over time in Parkinson’s disease. Neurology 2002; 58(10): 1544–1546.Google Scholar

Emre, M, Aarsland, D, Albanese, A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–2518.Google Scholar

Dubois, B, Tolosa, E, Katzenschlager, R, et al. Donepezil in Parkinson’s disease dementia: a randomized, double‐blind efficacy and safety study. Mov Disord 2012; 27: 1230–1238.CrossRef Google Scholar PubMed

Aarsland, D, Ballard B, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8(7): 613–618.CrossRef Google Scholar PubMed